PT - JOURNAL ARTICLE AU - Bastien, Etienne AU - Lefèvre-Arbogast, Sophie AU - Lequesne, Justine AU - Gernier, François AU - Cherifi, François AU - Rigal, Olivier AU - Guittet, Lydia AU - Grellard, Jean-Michel AU - Binarelli, Giulia AU - Lange, Marie AU - Fernette, Marie AU - Tron, Laure AU - Morel, Adeline AU - Richard, Doriane AU - Griffon, Bénédicte AU - Leconte, Alexandra AU - Quilan, Florian AU - Pépin, Louis-Ferdinand AU - Jardin, Fabrice AU - Leheurteur, Marianne AU - Faveyrial, Audrey AU - Clarisse, Bénédicte AU - Joly, Florence TI - Post-traumatic stress symptoms in cancer patients during the COVID-19 pandemic: a one-year longitudinal study AID - 10.1101/2022.01.11.22269053 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.11.22269053 4099 - http://medrxiv.org/content/early/2022/01/13/2022.01.11.22269053.short 4100 - http://medrxiv.org/content/early/2022/01/13/2022.01.11.22269053.full AB - Background Cancer patients may be particularly vulnerable to psychological consequences of the COVID-19 pandemic and successive lockdowns. We studied the prevalence and evolution of post-traumatic stress disorder (PTSD) symptoms in cancer patients during the pandemic waves, and investigated factors associated with high symptoms.Methods COVIPACT is a one-year longitudinal prospective study of French patients with solid/hematologic malignancy receiving treatment during the first nationwide lockdown. PTSD symptoms were measured every 3 months from April 2020 using the Impact of Event Scale-Revised. Patients also completed validated questionnaires on quality of life (QoL), cognitive complaints and insomnia, and a survey on their COVID-19 lockdown experience.Results Longitudinal analyses involved 386 patients with at least one PTSD assessment after baseline (median age 63, 76% female). Among them, 21.5% had moderate/severe PTSD symptoms during the first lockdown. The rate of patients reporting PTSD symptoms decreased at lockdown release (13.6%), increased again at second lockdown (23.2%), and slightly declined from the second release period (22.7%) to the third lockdown (17.5%). Patients were grouped into three trajectories of evolution. Most patients had stable low symptoms throughout the period, 6% had high baseline symptoms slowly decreasing over time, and 17.6% had moderate symptoms worsening during second lockdown. Female sex, feeling socially isolated, worrying about COVID-19 infection, and using psychotropic drugs were associated with PTSD symptoms. PTSD symptoms were associated with impaired QoL, sleep and cognition.Conclusions Around a quarter of cancer patients presented high and persistent PTSD symptoms over the first year of the COVID-19 pandemic and may benefit from psychological support.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a research grant from Fondation ARC (COVID202001320) and financial support from the GEFLUC Normandie (Les Entreprises Contre le Cancer/Campaigns Against Cancer, Rouen-Normandie).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for the study was obtained from the local ethics committee (ref. 220 C07; South Mediterranean II Committee for the Protection of Persons). The study was conducted in compliance with the French research standard (MR-003 "Research in the Field of Health Without Collection of Consent"; compliance commitment to MR-003 for the Francois Baclesse Center [no. 2146328 v.0, dated from January 26, 2018]). All patients received information, and none expressed any opposition to the use of their data. The trial is registered as ID RCB: 2020-A00879-30, ClinicalTrials NCT04366154.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available upon reasonable request to the corresponding author.